These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 36546383)
1. Drug Approved to Prevent Cisplatin-Associated Ototoxicity in Children. Aschenbrenner DS Am J Nurs; 2023 Jan; 123(1):23. PubMed ID: 36546383 [TBL] [Abstract][Full Text] [Related]
2. Sodium Thiosulfate: Pediatric First Approval. Dhillon S Paediatr Drugs; 2023 Mar; 25(2):239-244. PubMed ID: 36517667 [TBL] [Abstract][Full Text] [Related]
3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. van As JW; van den Berg H; van Dalen EC Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591 [TBL] [Abstract][Full Text] [Related]
4. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer. Freyer DR; Brock P; Knight K; Reaman G; Cabral S; Robinson PD; Sung L Lancet Child Adolesc Health; 2019 Aug; 3(8):578-584. PubMed ID: 31160205 [TBL] [Abstract][Full Text] [Related]
5. Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity. Mukherjea D; Dhukhwa A; Sapra A; Bhandari P; Woolford K; Franke J; Ramkumar V; Rybak L Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):965-982. PubMed ID: 32757852 [TBL] [Abstract][Full Text] [Related]
6. Prevention of emesis by tropisetron in children receiving combined chemotherapy with cisplatin. Berberoglu S Pediatr Hematol Oncol; 1995; 12(5):479-83. PubMed ID: 8519633 [TBL] [Abstract][Full Text] [Related]
7. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Freyer DR; Brock PR; Chang KW; Dupuis LL; Epelman S; Knight K; Mills D; Phillips R; Potter E; Risby D; Simpkin P; Sullivan M; Cabral S; Robinson PD; Sung L Lancet Child Adolesc Health; 2020 Feb; 4(2):141-150. PubMed ID: 31866182 [TBL] [Abstract][Full Text] [Related]
8. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Santos NAGD; Ferreira RS; Santos ACD Food Chem Toxicol; 2020 Feb; 136():111079. PubMed ID: 31891754 [TBL] [Abstract][Full Text] [Related]
9. Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials. Whitmore JB; Kris MG; Hesketh PJ; Grote TH; DuBois DM; Cramer MB; Hahne WF Support Care Cancer; 1998 Sep; 6(5):473-8. PubMed ID: 9773466 [TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Fauser AA; Pizzocaro G; Schueller J; Khayat D; Wilkinson P Support Care Cancer; 2000 Jan; 8(1):49-54. PubMed ID: 10650898 [TBL] [Abstract][Full Text] [Related]
11. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group. Lebeau B; Depierre A; Giovannini M; Rivière A; Kaluzinski L; Votan B; Hédouin M; d'Allens H Ann Oncol; 1997 Sep; 8(9):887-92. PubMed ID: 9358940 [TBL] [Abstract][Full Text] [Related]
13. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. van As JW; van den Berg H; van Dalen EC Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156 [TBL] [Abstract][Full Text] [Related]